ESC 2022 | INVICTUS and PRE18FFIR

On the 3erd day of the European Cardiology Congress 2022 the INVICTUS study was presented, including 4565 patients with atrial fibrillation secondary to rheumatism driven CAD. The aim of this study was to compare the use of Rivaroxaban vs vitamin K antagonists (VKA) in this populations. Mean age was 50 and most patients were women. 

ESC 2022

Primary end point was stroke, systemic thromboembolism, AMI, or cardiovascular death. Study outcomes resulted in 560 primary end point events in the rivaroxaban group vs 446 events in the VKA group (HR 1.25; 95% CI 1.10-1.41). On individual analysis, Rivaroxaban increased the risk of death by 23% and stroke by 37%. However, there were no differences in risk of bleeding between the groups. Drug discontinuation was more frequent in the Rivaroxaban group. 

Among rivaroxaban patients, when looking at RIN valued before study kickoff, within therapeutic range, it was 33%, and at follow-up, it reached 64% in 4 years. 

The use of vitamin K antagonists should be the standard treatment for rheumatic atrial fibrillation. We need further study to properly assess the different therapies for this special population. 

On the other hand, a multicenter prospective study was presented, the PRE18FFIR, which used sodium fluoride positron emission tomography scan (PET) to identify vulnerable plaque without the need for intravascular ultrasound imaging, predicting the risk of future cardiovascular events. 704 AMI and multivessel patients were included. They all received PET and coronary CT angiography and were followed up to 2 years. 

Read also: ESC 2022 | SECURE Trial.

There were no differences between patients with active coronary microcalcification and those who did not present any. However, when looking at cardiovascular death or AMI, events rate was higher among patients with positive PET imaging for CMA. 

This study shows an important role for PET in the assessment of cardiovascular risk. 

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Is it safe to use negative chronotropic drugs early after TAVI?

TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Dual Antiplatelet Therapy in Diabetic Patients with AMI: De-Escalation Strategy

Diabetes Mellitus (DM) is a common comorbidity in patients hospitalized for acute coronary syndrome (ACS) of increasing prevalence over the last decade, associated with...

AHA 2025 | OPTIMA-AF: 1 Month vs. 12 Months of Dual Therapy (DOAC + P2Y12) After PCI in Atrial Fibrillation

Concomitant atrial fibrillation (AF) and coronary artery disease is a common occurrence in clinical practice. In these patients, current guidelines recommend 1 month of...

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially considering the very low residual embolic risk...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Transcatheter Deep Vein Arterialization in Critical Limb Ischemia Without Revascularization Options

Chronic limb-threatening ischemia in patients without conventional revascularization options represents one of the most challenging scenarios within peripheral arterial disease, with 1-year major amputation...

Transcatheter Paravalvular Leak Closure: Mid-Term Outcomes and Prognostic Factors

Paravalvular leaks (PVL) are a frequent complication following surgical valve replacement, occurring in 5% to 18% of prosthetic valves. Incidence varies according to valve...

After a Major Bleeding Event in Atrial Fibrillation: When Should Left Atrial Appendage Closure Be Considered?

Atrial fibrillation (AF) in patients who experience a major bleeding event represents a complex clinical scenario in which percutaneous left atrial appendage closure (LAAC)...